Sign in
Taking people in Hong KongNo phase

Observes brexpiprazole use in real-life care for schizophrenia and depression

Follows adults with psychosis or depression who take brexpiprazole in routine care.

Key facts

Who runs it
Dr. Albert Kar-Kin Chung
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
Status
Recruiting
People taking part
40 people, planned
Started
1 Jul 2023
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Brexpiprazole
Record updated
8 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with a psychotic or depressive disorder who started brexpiprazole less than 4 weeks ago.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
A diagnosis of a psychotic disorder or depression (DSM-5 or ICD-10, codes F10-F19.5, F20-23, F25, F32-F33).
Earlier treatment
Must have been receiving brexpiprazole for less than 4 weeks at the time of joining.

Main reasons for not taking part

  • Younger than 18 years
  • Cannot read English or Chinese
  • Cannot give informed consent
  • Diagnosed with intellectual disability or mental retardation (ICD-10 F70-73)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age: 18- 65 years old at the time of enrollment
  • Able to read and communicate in English and/or Chinese
  • Able to give informed consent
  • Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33)
  • is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment

Who cannot take part

  • Age <18 years old
  • Unable to read English or Chinese
  • Unable to give informed consent
  • Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in Hong Kong

  • Queen Mary HospitalHong Kong, Hong KongContact: Albert KK ChungTaking people

About the trial

What the trial wants to find out

Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.

Treatments tested

  • Brexpiprazole

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
Plain-language title
Observes brexpiprazole use in real-life care for schizophrenia and depressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05962216, who can take part
Record updated
8 July 2025